Kalvista Pharmaceuticals shares fall 3.16% premarket after reporting a net loss of $183.44 million for the fiscal year ended April 30, 2025.

Kalvista Pharmaceuticals, Inc. fell 3.16% in premarket trading, following the release of its financial results for the fiscal year ended April 30, 2025. The company reported a net loss of $183.44 million, compared to $126.64 million in the previous year. The diluted loss per share from continuing operations was $3.69, compared to $3.44 in the prior year.